Tocagen and NRG Oncology, a member of the National Cancer Institute’s National Clinical Trial Network, announced that the NCI Cancer Therapy and Evaluation Program Brain Malignancies Steering Committee has approved a concept to develop a clinical trial utilizing the investigational therapeutic regimen Toca 511 for the treatment of patients with newly diagnosed glioblastoma. NRG Oncology conducts practice-defining, multi-institutional Phase 2 and 3 trials funded primarily by the NCI. The proposed Phase 2/3 trial is expected to begin enrollment in 2019 and will be conducted by NRG Oncology with Tocagen supplying investigational drug and supplemental financial support. Additional information about the trial will be provided in 2019. Tocagen is currently studying Toca 511 & Toca FC for the treatment of recurrent high grade glioma in the ongoing Phase 3 trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.